MHRA Inspection Prompts European Review Of US Firm's Drug Products
This article was originally published in The Gold Sheet
Pharmaceutics International must suspend manufacturing of commercial and investigational medicinal products largely for failure to manage cross-contamination risks appropriately, according to EU GMP non-compliance notice. Resumption of IMP production will hinge on approval of trial-by-trial risk assessments.
Register for our free email digests: